BACKGROUND: A consensus statement released on behalf of the Swiss Federal Commission for HIV/AIDS suggests that people receiving effective antiretroviral therapy-ie, those with undetectable plasma HIV RNA (<40 copies per mL)-are sexually non-infectious. We analysed the implications of this statement at a population level. METHODS: We used a simple mathematical model to estimate the cumulative risk of HIV transmission from effectively treated HIV-infected patients (HIV RNA <10 copies per mL) over a prolonged period. We investigated the risk of unprotected sexual transmission per act and cumulatively over many exposures, within couples initially discordant for HIV status. FINDINGS: Assuming that each couple had 100 sexual encounters per year, the cumulative probability of transmission to the serodiscordant partner each year is 0.0022 (uncertainty bounds 0.0008-0.0058) for female-to-male transmission, 0.0043 (0.0016-0.0115) for male-to-female transmission, and 0.043 (0.0159-0.1097) for male-to-male transmission. In a population of 10 000 serodiscordant partnerships, over 10 years the expected number of seroconversions would be 215 (80-564) for female-to-male transmission, 425 (159-1096) for male-to-female transmission, and 3524 (1477-6871) for male-to-male transmission, corresponding to an increase in incidence of four times compared with incidence under current rates of condom use. INTERPRETATION: Our analyses suggest that the risk of HIV transmission in heterosexual partnerships in the presence of effective treatment is low but non-zero and that the transmission risk in male homosexual partnerships is high over repeated exposures. If the claim of non-infectiousness in effectively treated patients was widely accepted, and condom use subsequently declined, then there is the potential for substantial increases in HIV incidence. FUNDING: Australian Research Council.
BACKGROUND: A consensus statement released on behalf of the Swiss Federal Commission for HIV/AIDS suggests that people receiving effective antiretroviral therapy-ie, those with undetectable plasma HIV RNA (<40 copies per mL)-are sexually non-infectious. We analysed the implications of this statement at a population level. METHODS: We used a simple mathematical model to estimate the cumulative risk of HIV transmission from effectively treated HIV-infectedpatients (HIV RNA <10 copies per mL) over a prolonged period. We investigated the risk of unprotected sexual transmission per act and cumulatively over many exposures, within couples initially discordant for HIV status. FINDINGS: Assuming that each couple had 100 sexual encounters per year, the cumulative probability of transmission to the serodiscordant partner each year is 0.0022 (uncertainty bounds 0.0008-0.0058) for female-to-male transmission, 0.0043 (0.0016-0.0115) for male-to-female transmission, and 0.043 (0.0159-0.1097) for male-to-male transmission. In a population of 10 000 serodiscordant partnerships, over 10 years the expected number of seroconversions would be 215 (80-564) for female-to-male transmission, 425 (159-1096) for male-to-female transmission, and 3524 (1477-6871) for male-to-male transmission, corresponding to an increase in incidence of four times compared with incidence under current rates of condom use. INTERPRETATION: Our analyses suggest that the risk of HIV transmission in heterosexual partnerships in the presence of effective treatment is low but non-zero and that the transmission risk in male homosexual partnerships is high over repeated exposures. If the claim of non-infectiousness in effectively treated patients was widely accepted, and condom use subsequently declined, then there is the potential for substantial increases in HIV incidence. FUNDING: Australian Research Council.
Authors: Caroline Mitchell; Jane Hitti; Kathleen Paul; Kathy Agnew; Susan E Cohn; Amneris E Luque; Robert Coombs Journal: AIDS Res Hum Retroviruses Date: 2010-10-07 Impact factor: 2.205
Authors: Deborah Donnell; Jared M Baeten; James Kiarie; Katherine K Thomas; Wendy Stevens; Craig R Cohen; James McIntyre; Jairam R Lingappa; Connie Celum Journal: Lancet Date: 2010-05-26 Impact factor: 79.321
Authors: Michael V O'Shaughnessy; Robert S Hogg; Steffanie A Strathdee; Julio S G Montaner Journal: Curr HIV/AIDS Rep Date: 2012-12 Impact factor: 5.071
Authors: Anders Ragnarsson; Anna Mia Ekström; Jane Carter; Festus Ilako; Abigail Lukhwaro; Gaetano Marrone; Anna Thorson Journal: J Int AIDS Soc Date: 2011-04-18 Impact factor: 5.396
Authors: Seth C Kalichman; Chauncey Cherry; Moira O Kalichman; Christina M Amaral; Denise White; Howard Pope; Connie Swetzes; Lisa Eaton; Rene Macy; Demetria Cain Journal: Am J Public Health Date: 2011-01-13 Impact factor: 9.308
Authors: Evelyn Byrd Quinlivan; Shilpa N Patel; Catherine A Grodensky; Carol E Golin; Hsiao-Chuan Tien; Marcia M Hobbs Journal: Sex Transm Dis Date: 2012-09 Impact factor: 2.830
Authors: Jolly Beyeza-Kashesya; Anna Mia Ekstrom; Frank Kaharuza; Florence Mirembe; Stella Neema; Asli Kulane Journal: BMC Public Health Date: 2010-05-13 Impact factor: 3.295